Baseline characteristics of patients included in the study (N = 400)
| Characteristic . | Admitted, not critically ill (n = 256) . | Critically ill (n = 144) . |
|---|---|---|
| Age, mean (range), y | 60 (23-99) | 65 (32-97) |
| Female, % | 47.3 | 35.4 |
| Race | ||
| White | 148 (57.8) | 95 (66.0) |
| Black | 43 (16.8) | 17 (11.8) |
| Asian or Pacific islander | 13 (5.1) | 6 (4.2) |
| Other | 42 (16.4) | 15 (10.4) |
| Not specified | 10 (3.9) | 11 (7.6) |
| Ethnicity, Hispanic or Latino | 74 (28.9) | 42 (29.2) |
| Hospitalization status | ||
| Discharged | 205 (80.1) | 18 (12.5) |
| Still admitted at end of study period | 49 (19.1) | 99 (68.75) |
| Deceased | 2 (0.8) | 27 (18.75) |
| Hospital length of stay, mean (range), d | ||
| Hospitalization complete | 6 (1-24) | 9 (2-23) |
| Hospitalization ongoing | 8 (2-18) | 12 (3-33) |
| Baseline anticoagulation | ||
| None (mechanical thromboprophylaxis only) | 9 (3.5) | 2 (1.4) |
| Standard prophylactic anticoagulation* | 230 (89.8) | 124 (86.1) |
| Intermediate or full-dose anticoagulation† | 17 (6.6) | 18 (12.5) |
| BMI, kg/m2 | ||
| Underweight (<18.5) | 3 (1.2) | 0 (0.0) |
| Normal weight (18.5-24.9) | 55 (21.5) | 28 (19.5) |
| Overweight (25.0-29.9) | 95 (37.1) | 54 (37.5) |
| Class I obesity (30.0-34.9) | 56 (21.9) | 29 (20.1) |
| Class II obesity (35.0-39.9) | 29 (11.3) | 20 (13.9) |
| Class III obesity (≥40.0) | 18 (7.0) | 13 (9.0) |
| Risk factors for severe COVID-19 | ||
| Cardiovascular disease | 82 (32.0) | 43 (29.9) |
| Chronic lung disease | 53 (20.7) | 25 (17.4) |
| Diabetes mellitus | 65 (25.4) | 58 (40.3) |
| Immune compromise or suppression | 29 (11.3) | 20 (13.9) |
| Chronic kidney disease on dialysis | 4 (1.6) | 6 (4.2) |
| Chronic liver disease | 13 (5.1) | 6 (4.2) |
| Reside in nursing home or long-term care facility | 21 (8.2) | 7 (4.9) |
| Characteristic . | Admitted, not critically ill (n = 256) . | Critically ill (n = 144) . |
|---|---|---|
| Age, mean (range), y | 60 (23-99) | 65 (32-97) |
| Female, % | 47.3 | 35.4 |
| Race | ||
| White | 148 (57.8) | 95 (66.0) |
| Black | 43 (16.8) | 17 (11.8) |
| Asian or Pacific islander | 13 (5.1) | 6 (4.2) |
| Other | 42 (16.4) | 15 (10.4) |
| Not specified | 10 (3.9) | 11 (7.6) |
| Ethnicity, Hispanic or Latino | 74 (28.9) | 42 (29.2) |
| Hospitalization status | ||
| Discharged | 205 (80.1) | 18 (12.5) |
| Still admitted at end of study period | 49 (19.1) | 99 (68.75) |
| Deceased | 2 (0.8) | 27 (18.75) |
| Hospital length of stay, mean (range), d | ||
| Hospitalization complete | 6 (1-24) | 9 (2-23) |
| Hospitalization ongoing | 8 (2-18) | 12 (3-33) |
| Baseline anticoagulation | ||
| None (mechanical thromboprophylaxis only) | 9 (3.5) | 2 (1.4) |
| Standard prophylactic anticoagulation* | 230 (89.8) | 124 (86.1) |
| Intermediate or full-dose anticoagulation† | 17 (6.6) | 18 (12.5) |
| BMI, kg/m2 | ||
| Underweight (<18.5) | 3 (1.2) | 0 (0.0) |
| Normal weight (18.5-24.9) | 55 (21.5) | 28 (19.5) |
| Overweight (25.0-29.9) | 95 (37.1) | 54 (37.5) |
| Class I obesity (30.0-34.9) | 56 (21.9) | 29 (20.1) |
| Class II obesity (35.0-39.9) | 29 (11.3) | 20 (13.9) |
| Class III obesity (≥40.0) | 18 (7.0) | 13 (9.0) |
| Risk factors for severe COVID-19 | ||
| Cardiovascular disease | 82 (32.0) | 43 (29.9) |
| Chronic lung disease | 53 (20.7) | 25 (17.4) |
| Diabetes mellitus | 65 (25.4) | 58 (40.3) |
| Immune compromise or suppression | 29 (11.3) | 20 (13.9) |
| Chronic kidney disease on dialysis | 4 (1.6) | 6 (4.2) |
| Chronic liver disease | 13 (5.1) | 6 (4.2) |
| Reside in nursing home or long-term care facility | 21 (8.2) | 7 (4.9) |